This paper, as part of the special issue on “Hijacking the metabolic regulation in cancer and diabetes,” aims to highlight the complications arising from targeting the SphK1/S1P rheostat, by the S1P modulators, for cancer therapy in patients with prediabetes/diabetes. Here, SPHK1 is linked to cancer.